IDH2 and acute myeloid leukemia: By using RNA-seq data to expand our sample size and automating the alignment and variant calling process in bamSliceR, we document statistically and clinically significant co-occurrence of oncometabolic IDH2 variants with high-risk H3K27 pAML mutant cases, yielding testable hypotheses and new translational avenues (Thomas et al. 2023) for a subset of AML patients at high risk of treatment failure.